GENETIC, VIRAL & IMMUNOLOGIC STUDIES IN NEW ZEALAND MICE
遗传、病毒
基本信息
- 批准号:7024553
- 负责人:
- 金额:$ 34.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1979
- 资助国家:美国
- 起止时间:1979-07-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyteanergyapoptosisautoantibodyautoimmune disorderbiotechnologybiotherapeutic agentdendritic cellsgenetically modified animalshelper T lymphocytehistopathologyhumoral immunityimmunofluorescence techniqueimmunogeneticsimmunologic assay /testimmunologic substance development /preparationlaboratory mouseleukocyte depletion therapynucleosomessynthetic vaccinessystemic lupus erythematosusthymus
项目摘要
DESCRIPTION (provided by applicant):
The objectives are to understand why the lupus immune system responds abnormally to nucleosomes, the major products of physiologically programmed apoptosis, and how can such autoimmune responses be specifically down-regulated? Identification of the dominant epitopes in nucleosomes critical for cognate interactions between autoimmune T helper (Th) cells and anti-DNA B cells of lupus provided us the essential tools for two novel discoveries leading to the proposed experiments. 1). It is widely believed that negative selection is intact in lupus. We have now found that the thymuses of lupus-prone mice are unable to delete transgenic thymocytes bearing nucleosome-specific T-cell receptor (TCR), although central tolerance for other antigens is intact. For the first time, mechanism/s of this peculiarly selective defect in central tolerance for nucleosomes in the lupus-prone thymus will be defined using new lines of TCR-transgenic mice we have generated. Mice of normal backgrounds bearing the transgenes will be studied first to define mechanism/s of negative selection of T cells specific for nucleosomes, the major products of ongoing apoptosis in the thymus, and to define the spectrum of negatively selecting epitopes. Novel mechanisms of peripheral tolerance in these new transgenic mice bearing lupus TCR will also be studied, particularly a functional uncoupling of signaling by autoimmune TCR from full T cell activation.
2). We have found that therapeutic tolerance with very low doses of select nucleosomal peptides can down-regulate active lupus by unique mechanisms. The critical epitopes that are recognized in MHC unrestricted manner by pathogenic autoantibody-inducing Th cells of lupus are also recognized by autoimmune B cells, and such shared epitopes are potent tolerogens for therapy. We will determine how pathogenic autoantibody inducing help is impaired by very low-dose vs. high-dose tolerance therapy with the nucleosomal peptide epitope/s we have identified, a). Role of anergy or deletion of lupus T and B cells; b). role of long-lasting regulatory (suppressor) T cell subsets with unique markers that are generated by peptide therapy; and c). the roles of tolerogenic dendritic cells and B cells in the generation of unusual regulatory T cells will be defined. The studies will address fundamental questions regarding autoimmunity and tolerance to an ubiquitous product of apoptosis, and would help in developing antigen-specific therapy of lupus.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SYAMAL K DATTA其他文献
SYAMAL K DATTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SYAMAL K DATTA', 18)}}的其他基金
IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
- 批准号:
2882256 - 财政年份:1999
- 资助金额:
$ 34.45万 - 项目类别:
IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
- 批准号:
6137339 - 财政年份:1999
- 资助金额:
$ 34.45万 - 项目类别:
IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
- 批准号:
6341792 - 财政年份:1999
- 资助金额:
$ 34.45万 - 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
- 批准号:
2457949 - 财政年份:1993
- 资助金额:
$ 34.45万 - 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
- 批准号:
2748628 - 财政年份:1993
- 资助金额:
$ 34.45万 - 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
- 批准号:
6043194 - 财政年份:1993
- 资助金额:
$ 34.45万 - 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
- 批准号:
6374902 - 财政年份:1993
- 资助金额:
$ 34.45万 - 项目类别:
相似海外基金
Local immune modulation for beta cell replacement therapy in type 1 diabetes
1 型糖尿病 β 细胞替代疗法的局部免疫调节
- 批准号:
10596656 - 财政年份:2022
- 资助金额:
$ 34.45万 - 项目类别:
Development of Novel CD180-Based Cancer Immunotherapeutics
基于 CD180 的新型癌症免疫疗法的开发
- 批准号:
10381384 - 财政年份:2022
- 资助金额:
$ 34.45万 - 项目类别:
Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes
工程树突状细胞将胰岛抗原靶向促耐受性亚群,用于预防和治疗 1 型糖尿病
- 批准号:
10436038 - 财政年份:2022
- 资助金额:
$ 34.45万 - 项目类别:
Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes
工程树突状细胞将胰岛抗原靶向促耐受性亚群,用于预防和治疗 1 型糖尿病
- 批准号:
10595602 - 财政年份:2022
- 资助金额:
$ 34.45万 - 项目类别:
Local immune modulation for beta cell replacement therapy in type 1 diabetes
1 型糖尿病 β 细胞替代疗法的局部免疫调节
- 批准号:
10713402 - 财政年份:2022
- 资助金额:
$ 34.45万 - 项目类别:
T cell regulation by adult prostate stem cells
成体前列腺干细胞对 T 细胞的调节
- 批准号:
10382302 - 财政年份:2021
- 资助金额:
$ 34.45万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 34.45万 - 项目类别:
Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma
弥漫性大 B 细胞淋巴瘤 18q DNA 拷贝数增加的功能特征和合理治疗靶向
- 批准号:
10533731 - 财政年份:2020
- 资助金额:
$ 34.45万 - 项目类别:
Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma
弥漫性大 B 细胞淋巴瘤 18q DNA 拷贝数增加的功能特征和合理治疗靶向
- 批准号:
10304937 - 财政年份:2020
- 资助金额:
$ 34.45万 - 项目类别:
A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.
一种基于聚合生物材料的疫苗,利用免疫调节剂和抗原来改善 1 型糖尿病。
- 批准号:
10009981 - 财政年份:2020
- 资助金额:
$ 34.45万 - 项目类别: